Answer
Headache was reported in 9.2% of Brinsupri-treated patients with non-cystic fibrosis bronchiectasis in clinical trials and was classified as common.
Sources for this answer
- Brinsupri 25 mg film-coated tabletsInsmed Limited · emc · SmPC §4.8 Undesirable effects · Version 1Document updated
Sources checked